Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Cash & Equivalents (2021 - 2025)

Zymeworks' Cash & Equivalents history spans 3 years, with the latest figure at $94.3 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 1.82% year-over-year to $94.3 million; the TTM value through Sep 2023 reached $94.3 million, down 1.82%, while the annual FY2022 figure was $400.9 million, 98.6% up from the prior year.
  • Cash & Equivalents for Q3 2023 was $94.3 million at Zymeworks, down from $142.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $400.9 million in Q4 2022 and bottomed at $94.3 million in Q3 2023.
  • The 3-year median for Cash & Equivalents is $161.8 million (2023), against an average of $186.1 million.
  • The largest annual shift saw Cash & Equivalents surged 98.6% in 2022 before it dropped 1.82% in 2023.
  • A 3-year view of Cash & Equivalents shows it stood at $201.9 million in 2021, then soared by 98.6% to $400.9 million in 2022, then crashed by 76.47% to $94.3 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Cash & Equivalents are $94.3 million (Q3 2023), $142.1 million (Q2 2023), and $181.6 million (Q1 2023).